If this message does not appear correctly, click this link

Approval Of Inhibitor Larotrectinib Across Tumor Types– Are We Ready For The Era Of Tissue-Agnostic Targeted Cancer Therapy?

By Dr. Nina Lapke, Biomedical Informatics Scientist of ACT Genomics

Tissue-agnostic drug is a new way to treat cancer via biomarkers across tumor types, which brings precision medicine one step further to treat more patients properly. With clinical trials combining patients of various cancer types according to their tumor markers becoming more popular, it is only a matter of time until other tissue-agnostic drugs will obtain approval, driving further personalization of cancer therapy and improving patient outcomes.

Find Out More Insights

New Panel Launched! ACTFusion™ Grasps The Trend In Targeted Therapy

Image title

New progress in tumor treatment- ACTFusion™ can help you find biomarker in 182 fusion transcripts. Recent study shows that over 10% fusion genes were found in NSCLC and over 15% were found in Thyroid cancer, and in 2018 November, the FDA approved the first tumor agnostic treatment for those with TRK fusion based on the clinical benefits observed across numerous tumor types. Our new targeted, multi-biomarker assay - ACTFusion™examines 31 druggable fusion genes and182 transcripts included in the NCCN guidelines (e.g. ALK, ROS1, NTRK1/2/3) or tested in the global clinical trials (e.g. RET, MET, NRG1) to help patients find effective treatment.. 

Get Started On ACTFusion™

 First NGS Testing Results For Over 400 Cancer Patients In Taiwan 

Image title

ACT Genomics cooperates with the Chair, Department of Pathology, Chi Mei Medical Center, Taiwan, Dr. Chien-Feng Li to sequence FFPE for more than 400 cancer patients using NGS, and the patients across 20 cancer types such as breast cancer, lung cancer, colorectal cancer, liver cancer, kidney cancer, pancreatic cancer and gastric cancer were found with frequently seen druggable genetic alterations. Using NGS to sequence 440 cancer-related genes all at once can find effective treatment options for cancer patient efficiently. This research result was presented in the most influential annual event in cancer treatment in Taiwan, the 24th Taiwan Joint Cancer Conference in the session of  “Genomic Exploration By Using Next-Generation Sequencing In FFPE Samples: What Did We Learn?"

Help Your Patients To Sequence 440 Genes

ACTG Establishes Shonan iPark Laboratory To Develop Cancer Precision Medicine

Image title

More precision cancer medicine are available for clinical needs and drug development in Japan! Find out more at the new analysis laboratory "Shonan iPark Laboratory" of ACTmed, a joint venture between Canon Medical Systems and ACT Genomics in Japan. With the laboratory, ACTmed will offer precision cancer medicine to fulfill the clinical needs and drug development activities in Japan, making it possible to provide comprehensive services to quickly address requests from clients and promptly respond to their inquiries. Full-scale operation is scheduled to commence in July 2019.

Shonan iPark Laboratory News Report

LOXO-195 Shows Good Activity In Patients Who Have Failed After Prior Anti-TRK Therapy

In a phase 1 study, LOXO-195 showed promising results in multiple cancer types after failure of initial anti-TRK therapy.

Learn More

Maintenance Rucaparib Shows Encouraging Disease Control In Pancreatic Cancer Patients With BRCA1, BRCA2 Or PALB2 Mutation

Rucaparib maintenance following platinum-based chemotherapy shows encouraging disease control in BRCA1/2 or PALB2-mutant pancreatic cancer.

Learn More

MET Amplification Is A Potential Biomarker For NSCLC Patients Resistant To 1st And 2nd EGFR Inhibitor Treatment

A phase Ib clinical trial (TATTON) data revealed the efficacy of osimertinib plus savolitinib in MET-amplified NSCLC patients after progression on EGFR inhibitor treatment.

Learn More

Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :